| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 21004 |
| Drug | Niraparib |
| Brand | Zejula® |
| Indication | Is indicated as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 22/02/2021 |
| Rapid review completed | 26/03/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of niraparib (Zejula®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/03/2021 |
| Pre-submission consultation with Applicant | 01/06/2021 |
| Full submission received from Applicant | 18/10/2021 |
| Preliminary review sent to Applicant | 14/06/2022 |
| NCPE assessment re-commenced | 28/07/2022 |
| Factual accuracy sent to Applicant | 31/08/2022 |
| NCPE assessment re-commenced | 07/09/2022 |
| NCPE assessment completed | 26/09/2022 |
| NCPE assessment outcome | The NCPE recommends that niraparib (Zejula®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations April 2023.
